Evidence map›Paper›PMID 40167833›Full record

ArticleMolecular biology reports2025

Aquaporin 3 inhibition attenuates imiquimod-induced psoriatic symptoms in a murine model.

Ryosuke Okubo, Manami Tanaka, Akiharu Kubo, Masato Yasui, Mariko Hara-Chikuma

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ryosuke Okubo *Department of Pharmacology, School of Medicine, Keio University, Tokyo, 160-8582, Japan.
Manami Tanaka *Department of Pharmacology, School of Medicine, Keio University, Tokyo, 160-8582, Japan.
Akiharu KuboDepartment of Dermatology, School of Medicine, Keio University, Tokyo, Japan.
Masato YasuiDepartment of Pharmacology, School of Medicine, Keio University, Tokyo, 160-8582, Japan.
Mariko Hara-ChikumaDepartment of Pharmacology, School of Medicine, Keio University, Tokyo, 160-8582, Japan. mariko.chikuma@keio.jp.

Funding

Research Ministry of Education, Culture, Sports, Science 21K06974
6 · The paper itself

Abstract

backgroundAquaporin 3 (AQP3) is highly expressed in both keratinocytes and T cells within psoriatic skin. Previous studies have demonstrated that AQP3 knockout mice show reduced development of psoriatic symptoms in murine models. This study aims to evaluate the effect of AQP3 inhibition on psoriasis progression. METHODS AND

resultsAQP3 conditional knockout mice were generated to assess the role of AQP3 expression in keratinocytes and T cells in psoriasis pathogenesis. In an imiquimod (IMQ)-induced psoriasis model, psoriatic symptoms were significantly reduced in mice with keratinocyte-specific AQP3 deletion. Additionally, AQP3 inhibition by administration of anti-AQP3 monoclonal antibody (mAb) effectively alleviated IMQ-induced psoriasis symptoms in wild-type mice.

conclusionsAQP3 inhibition presents a promising approach for the treatment of psoriasis.

Indexed as

Aquaporin 3PsoriasisAnimalsAntibodies, MonoclonalDisease Models, AnimalImiquimodKeratinocytesMiceMice, Inbred C57BLMice, KnockoutSkinT-LymphocytesAntibodies, MonoclonalAqp3 protein, mouseAquaporin 3ImiquimodAntibody therapyAquaporin 3Psoriasis

Identifiers

PMID40167833

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.